Trastuzumab Plus Docetaxel in HER-2/neu-Positive Prostate Carcinoma: Final Results from the California Cancer Consortium Screening and Phase II Trial

Cancer

Volumn 100, Issue 10, 2004, Pages 2125-2131

  Lara Jr , Primo N ^a,c   Chee, Karen Giselle ^a   Longmate, Jeff ^b   Ruel, Christopher ^b   Meyers, Frederick J ^a   Gray, Carl R ^a   Edwards, Regina Gandour ^a   Gumerlock, Paul H ^a   Twardowski, Przemyslaw ^b   Doroshow, James H ^b   Gandara, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c SANOFI   (France)

Author keywords

Docetaxel; HER 2 neu; Hormone refractory prostate carcinoma; Trastuzumab

Indexed keywords

DOCETAXEL; NEU ONCOPROTEIN; ONCOPROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MIXTURE; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; TAXOIDS; TREATMENT OUTCOME; UP-REGULATION;

EID: 2342456382     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20228     Document Type: Article

References (38)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics 2003. CA Cancer J Clin. 2003;53:5-26.
2. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-1764.
3. Martel CL, Gumerlock PH, Meyers FJ, Lara PN. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev. 2003;29:171-187.
4. Foster CS, Gosden CM, Ke Y. HER2/neu expression in cancer: the pathologist as diagnostician or prophet? Hum Pathol. 2003;34:635-638.
5. Marengo SR, Sikes RA, Anezinis P, Chang SM, Chung LW. Metastasis induced by overexpression of p185neu-T after orthotopic injection into a prostatic epithelial cell line (NbE). Mol Carcinog. 1997;19:165-175.
6. Craft N, Shostak Y, Carey M, et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the Her-2 tyrosine kinase. Nat Med. 1999;5:280-285.
7. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
8. Giatromanolaki A, Koukourakis MI, O'Bryne K, et al. Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. Anticancer Res. 1996;16:3819-3826.
9. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894-2904.
10. Ross JS, Nazeer T, Church K, et al. Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer. 1993;72:3020-3028.
11. Saffari B, Jones LA, el-Naggar A, et al. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res. 1995;55: 5693-5698.
12. Zhau HE, Zhang X, von Eschenbach AC, et al. Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol Carcinog. 1990;3:254-257.
13. Ranzani GN, Pellegata NS, Previdere C, et al. Heterogeneous protooncogene amplification correlates with tumor progression and presence of metastases in gastric cancer patients. Cancer Res. 1990;50:7811-7814.
14. Press MF, Pike MC, Hung G, et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. 1994;54: 5675-5682.
15. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
16. Hudziak RM, Lewis GD, Winget M, et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitized human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989;9:1165-1172.
17. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-4289.
18. Shepard HM, Lewis GD, Sarup JC, et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol. 1991;11:117-127.
19. Wright GL, Grob M, Huang C, et al. Comparison of Her-2/neu in prostate and breast carcinomas [abstract]. Proc Am Assoc Cancer Res. 1995;36:A3837.
20. Zhau HE, Wan DS, Zhou I, et al. Expression of C-erb b-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. Mol Carcinog. 1992;5:320-327.
21. Signoretti S, Montironi R, Manola J, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst. 2000;92:1918-1925.
22. Craft P, Raitano A, Redulla J, et al. Overexpression of the Her-2/neu receptor tyrosine kinase confers androgen-independent prostate cancer growth [abstract]. Proc Am Assoc Cancer Res. 1997;38:A463.
23. Mark HF, Feldman D, Das S, et al. Fluorescence in situ hybridization study of Her-2/neu oncogene amplification in prostate cancer. Exp Mol Pathol. 1999;66:170-178.
24. Liu HL, Gandour-Edwards R, Lara PN, et al. Detection of low levels of Her-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization. Cancer J. 2001;7:395-403.
25. Lara P Jr., Meyers F, Gray C, et al. Her-2/neu is overexpressed infrequently in patients with prostate carcinoma: results from the California Cancer Consortium screening trial. Cancer. 2002;94:2584-2589.
26. Shi Y, Brands FH, Chatterjee S, et al. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol. 2001;166:1514-1519.
27. Morote J, de Torres I, Caceres C, Vallejo C, Schwartz S Jr., Reventos J. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. Int J Cancer. 1999;84:421-425.
28. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med. 1999;5:280-285.
29. Mendoza N, Phillips GL, Silva J, Schwall R, Wickramasinghe D. Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res. 2002;62:5485-5488.
30. Agus DB, Scher HI, Higgins B, et al. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res. 1999;59:4761-4764.
31. Mass RD, Sanders C, Kasian C, et al. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin™ pivotal trials [abstract]. Proc Am Soc Clin Oncol. 2000;19:291.
32. Morris M, Reuter V, Kelly W, et al. A phase II trial of Herceptin alone and with Taxol for the treatment of prostate cancer [abstract]. Proc Am Soc Clin Oncol. 2000;19:1298.
33. Reese DM, Small EJ, Magrane G, Waldman FM, Chew K, Sudilovsky D. HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol. 2001;116:234-239.
34. van de Vijver MJ. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). Eur J Cancer. 2001;37:11-17.
35. Stearns V, Yamauchi H, Hayes DF. Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat. 1998;52:239-259.
36. Osman I, Scher HI, Drobnjak M, et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res. 2001;7:2643-2647.
37. Morris MJ, Reuter VE, Kelly WK, et al. HER-2 profiling and targeting in prostate carcinoma. Cancer. 2002;94:980-986.
38. Sanchez KM, Sweeney CJ, Mass R, et al. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a request for a standardized, organ specific methodology. Cancer. 2002; 95:1650-1655.